RGRX - RegeneRx Biopharmaceuticals, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.1000
-0.0071 (-6.59%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close0.1071
Open0.1000
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.0975 - 0.1071
52 Week Range0.0900 - 0.3100
Volume72,275
Avg. Volume46,650
Market Cap12.843M
Beta (3Y Monthly)2.20
PE Ratio (TTM)N/A
EPS (TTM)-0.00
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.50
Trade prices are not sourced from all markets
  • PR Newswire2 months ago

    RegeneRx Partner Updates on Clinical Trials

    "Regarding progress on ARISE-3, the manufacturing of the investigational product for ARISE-3 has been completed and the protocol for the study has been finalized and is now ready for the study. Also, since funding for the ARISE-3 clinical study is progressing smoothly towards the final stage, we will do our best to inform you of ARISE-3 study initiation as soon as possible.

  • PR Newswire3 months ago

    World Health Organization Recommends INN for Thymosin Beta 4 as "timbetasin"

    ROCKVILLE, Md., Sept. 6, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that the recommended INN (International Nonproprietary Name) for Thymosin Beta 4 is timbetasin, as published by the World Health Organization (WHO). The term "INN" is an official name given to a new active pharmaceutical ingredient as prescribed by the WHO and is given for the classification of substances. Any drug substance that has the characteristics of "Thymosin beta 4" that will be developed as a pharmaceutical product in the future must use the name "timbetasin", a term requested by GtreeBNT.  The common name, "timbetasin," was designated according to the guidelines for WHO INN naming and has a symbolic meaning that can be associated with Thymosin Beta 4.

  • PR Newswire4 months ago

    RegeneRx Licensee GtreeBNT Enters into Joint Venture to Globally Develop RGN-137 for Treatment of Epidermolysis Bullosa

    ROCKVILLE, Md., Aug. 2, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its licensee for RGN-137, GtreeBNT, has entered into a joint venture with YuYang DNU, a Korean company, to develop RGN-137 on a global basis for the orphan indication, epidermolysis bullosa (EB).  The joint venture between the two companies is Lenus Therapeutics, LLC (Lenus), a GtreeBNT U.S. subsidiary.  Gtree will contribute the intellectual property rights and all development results for RGN-137 and YuYang will invest about $17.8 million in cash into Lenus. According to GtreeBNT's press release, prior to a Phase 3 study planned for next year, Lenus is first planning to conduct an open study to attract big pharma, which has expressed ongoing interest in the product.  The Phase 3 trial is then expected to enroll approximately 200 subjects around the world, including in the U.S.

  • PR Newswire5 months ago

    RGN-259 (Tβ4) Improves Clinically Important Dry Eye Efficacies in Comparison with Prescription Drugs in Dry Eye Model

    The study was published on July 12, 2018, in the journal, Scientific Reports, an online open access scientific mega journal and part of the Nature Publishing Group.  The study was conducted by researchers who are either consultants to RegeneRx or, employees of, or consultants to GtreeBNT/ReGenTree LLC, a RegeneRx licensee for RGN-259 in North American and certain Asian territories.  Some of the study data were previously presented at the 2018 ARVO meeting in May 2018. RGN-259 is currently in Phase 3 clinical trials in the U.S. and been studied in approximately 1,000 patients.  In addition to the reported rapid onset of clinical efficacies, RGN-259 has not reported any significant side effects compared to other products currently approved for DES.

  • PR Newswire6 months ago

    RegeneRx Holds Annual Meeting

    ROCKVILLE, Md. , June 13, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)   ("the Company" or "RegeneRx"), today held its 2018 Annual Meeting.  Seventy-eight of ...

  • PR Newswire7 months ago

    RegeneRx Corrects Annual Meeting Date to Wednesday, June 13, 2018

    ROCKVILLE, Md. , May 29, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), today is correcting a misprinted annual meeting date in ...

  • PR Newswire7 months ago

    ReGenTree Presents Results of a Comparison Study of RGN-259 and Approved Prescription Drugs for Dry Eye Syndrome in a Mouse Model at ARVO

    ROCKVILLE, Md., May 2, 2018 /PRNewswire/ -- ReGenTree, LLC (the "Company"), a joint venture between GtreeBNT and RegeneRx Biopharmaceuticals (RGRX), announced today that the Company presented results of a comparison study of RGN-259 and marketed products for dry eye syndrome in a dry eye mouse model at ARVO (The Association for Research in Vision and Ophthalmology) meeting in Honolulu, Hawaii. Gabriel Sosne, M.D. at Wayne State University School of Medicine and Hynda Kleinman, Ph.D. at The George Washington University School of Medicine were among the authors of the study. The study found that RGN-259 treatment promoted recovery of mucins and goblet cells, improved corneal integrity, increased tears, and reduced inflammation in a dry eye mouse model.

  • PR Newswire8 months ago

    GtreeBNT Discloses Preliminary Observations from Seventeen NK Patients Treated with RGN-259 Eye Drops

    ROCKVILLE, Md. , April 25, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on ...

  • PR Newswire8 months ago

    RegeneRx Announces Outcome of FDA Discussions for Development of RGN-259 for Dry Eye Syndrome

    ROCKVILLE, Md., April 9, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced the outcome of discussions between its U.S. joint venture, ReGenTree LLC, and the FDA regarding the results of the completed phase 3 clinical trial (ARISE-2) and the future development requirements for a New Drug Application ("NDA") submission of RGN-259, a novel drug candidate to treat dry eye syndrome. "Although the FDA is requiring an additional phase 3 trial (ARISE-3) to further demonstrate efficacy in both signs and symptoms of dry eye in a larger patient population, all safety data from ARISE-1 and ARISE-2 were accepted by the FDA, no additional nonclinical efficacy and safety studies are required by the FDA, and the Company's chemistry and manufacturing control plans for the drug substance and drug product were considered complete and acceptable for NDA submission.

  • PR Newswire9 months ago

    RegeneRx Receives Notice of Allowance of U.S. Patent for Treatment of Corneal Wounds

    Corneal wounds can occur from refractive surgeries such as Lasik, eye disorders such as diabetic keratopathy and dry eye syndrome, and traumatic injuries related to abrasions and burns.   Infections, as well as contact lenses, can also play a role in the development of corneal wounds.  A simple-to-use, safe and effective eye drop to treat such wounds would address a significant unmet medical need. RegeneRx has licensed the U.S. rights to RGN-259, currently in phase 3 clinical trials in the U.S., to ReGenTree, LLC, a joint venture between GtreeBNT and RegeneRx.  RegeneRx retains full ownership of the intellectual property and knowhow related to RGN-259 in the EU.

  • PR Newswire9 months ago

    RegeneRx Receives "Decision to Grant" European Patent For Treatment of Peripheral Neuropathy

    ROCKVILLE, Md. , March 12, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on ...

  • PR Newswire9 months ago

    RegeneRx Secures $1 Million in Funding

    ROCKVILLE, Md., March 2, 2018 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that it entered into a Warrant Reprice Agreement whereby it received $1.03 million in warrant exercise proceeds. The warrant exercise proceeds should fund current operations into 2019.

  • PR Newswire10 months ago

    Key U.S. Dry Eye Patent Issued to RegeneRx

    ROCKVILLE, Md. , Feb. 22, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX)("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue ...

  • PR Newswire10 months ago

    RegeneRx Receives Canadian Patent for Treating Neurological Injury and Damage

    ROCKVILLE, Md. , Feb. 14, 2018 /PRNewswire/ --  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue ...